Viracta Therapeutics (Nasdaq: VIRX) closes NAVAL-1 trial and explores strategic options, impacting virus-associated cancer patients.

Unusual Whales
2025.02.03 16:11
On December 26, 2024, San Diego-based Viracta Therapeutics, Inc. (Nasdaq: VIRX), a company specializing in precision oncology for virus-associated cancers globally, revealed its Board of Directors' commencement of considering various strategic options.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.